A new experimental model of epilepsy, described by Gross and Weaver [J Cardiovasc Pharmacol 1993;22(suppl 8):282–7] was studied. Endothelin-1 (ET), synthesized by O. Kaurov and M. Smirnova (Saint Petersburg) was administrated into the lateral ventricle of rats. ET 9 pmol/μl was the threshold dose. High doses of ET induced death; lower doses were not effective. Behavior seizures and electrical activity of frontal cortex, amygdala, and hippocampus were recorded. Barrel rolling and generalized seizures were observed. Amygdala afterdischarges preceded the motor manifestations, which had a very short latency. Intraventricular administration of triol saponins of Korean red ginseng (before or after ET) and ginsenoside Rc inhibited the seizures and significantly increased latency. Inhibition of ET-I-induced barrel rolling and epileptic activity of limbic structures was independent on the interaction of ginsenosides with the GABA-benzodiazine–chloride channel receptor complex (Gen Pharmacol 1994;25:193–9). Intranasal application of ET-I in the same dose did not induce barrel rolling and seizures.

Catalepsy and Epilepsy in Rats: Common Factors? E. V. Petrova, E. L. J. M. van Luijtelaar, and G. D. Kuznetsova (Institute of Higher Nervous Activity and Neurophysiology, Moscow, Russia; and Department of Psychology, University of Nijmegen, Nijmegen, The Netherlands).

The cataleptic state is characterized by the presence of muscular rigidity, automatism, and myoclonus. These symptoms often occur in epileptic patients. In animal models, a relation between catalepsy and epilepsy also is sometimes reported. Petrova et al. (J Vysok Nerv Deyat 1992;42:1009–17) showed that genetic cataleptic rats have an increased predisposition for epileptiform activity, including signs of petit mal. In the present study, we investigated whether WAG/Rij rats, genetically endowed with generalized spike-wave discharges (SWD) are more sensitive for catalepsy.

WAG/Rij and Wistar rats, implanted with chronic EEG electrodes, were recorded for 15 min; rats were exposed to photic stimulation of 3, 10, and 25 Hz for 2–5 min periods and several days later to acoustic stimulation with key ringing.

WAG/Rij showed some behavioral signs of fear after both types of stimulation, and the EEG was periodically driven by the rhythm of the flashes; SWD were not observed. However, in the first 5 min after the end of the visual and auditory stimulation, 10 and 11 of 13 WAG/Rij became motionless and retained an uncomfortable pose when forced to sit on their sacrum. The number of SWD gradually increased and reached a maximum 5–10 min after the end of the stimulation. Wistar rats remained active after visual and auditory stimulation and manifested no sign of pathology in behavior or in EEG. Genetically epileptic WAG/Rij are more susceptible than Wistar rats to induction of a cataleptic state, suggesting that the mechanisms responsible for SWD and for catalepsy might be related.

Effects of Remacemide and Its Metabolite FPL 12495 on Spike-Wave Discharges, EEG, and Behavior in Rats with Absence Epilepsy. E. L. J. M. van Luijtelaar and A. M. L. Coenen (NICI, Department of Psychology, University of Nijmegen, Nijmegen, The Netherlands).

Anticonvulsant drugs may or may not be effective against generalized absence epilepsy. Carbamazepine and phenytoin aggravate spike-wave discharges (SWD) whereas valproate and benzodiazepines reduce SWD. The effects of the new anticonvulsant remacemide on SWD are unknown, which prompted us to investigate the effects of remacemide and its active metabolite FPL 12495 in a genetic rat model for absence epilepsy, the WAG/Rij strain. Number and mean duration of SWD, parameters of the background EEG and spontaneous behavior were measured after various oral doses of remacemide and FPL 12495.

A decrease in the number of SWD was noted after remacemide administration. At the highest dose, SWD were almost completely suppressed and there were no important effects on behavior or on spectral content of the background EEG, suggesting that remacemide has few side effects and might be effective against absence epilepsy. A decrease in the number of SWD was also noted after FPL 12495 gavage, but mean duration was prolonged. Behavioral changes were apparent only after the highest dose, accompanied by changes in spectral content, suggesting that FPL 12495 has other central effects as well. FPL 12495 appeared to be more potent than remacemide in all its effects.

The effects of FPL 12495 are unusual in that no other investigated drug has yet shown a decrease in number together with an increase in mean duration of discharges. FPL 12495 appears to exert a differential action on the two commonly distinguished mechanisms controlling number and duration.


Numerous studies have provided evidence for the involvement of opioids in the mechanisms of various forms of epilepsy. Most have investigated the effects of opioids in the control and genesis of convulsive epilepsy, whereas data on opioids mechanisms with respect to nonconvulsive epilepsy are almost lacking. Therefore, we investigated the role of the opioid subsystems in WAG/Rij rats, a genetic rat model of human absence epilepsy. Six-month-old male WAG/Rij were chronically provided with EEG electrodes and some with cannulas in the lateral ventricle. The baseline EEG was measured, and the drugs or solvent was injected. The EEG was recorded for 1 h, and the number and duration of spike-wave discharges (SWD) was counted.

SWD were facilitated by the nonspecific opioid antagonist naloxone (intraperitoneally), suggesting that SWD are tonically inhibited by the endogenous opioid system. Next, specific μ, δ, and κ agonists and antagonists were evaluated. The μ receptor agonist DAMGO induced intracerebroventricularly, i.c.v. markedly the number of SWD, whereas DPDPPE, a δ receptor agonist, had no effect. Three κappa agonists (i.e., subcutaneously) U50488H, U69593, or PD117301 dose-dependently inhibited the number of SWD. These effects could be antagonized by the kappa antagonist Nor-BNI. Nor-BNI itself enhanced the number of SWD, but the μ antagonist naltrindole had no effect.

Endogenous opioids, which act through the κappa receptors, tonically control the initiation of SWD. Kappa agonists, if devoid of psychomimetic effects, might be useful antiepileptics.

Effects of Tiagabine on Spike-Wave Discharges, Behavior, and Spectral Content of the EEG in Rats with Absence Epilepsy. A. M. L. Coenen, E. L. J. M. van Luijtelaar, and E. Blezer (Department of Psychology, University of Nijmegen, Nijmegen, The Netherlands).

The mechanism of action of the new anticonvulsant drug tiagabine (TGB) is reuptake inhibition of GABA. What TGB will do against nonconvulsive epilepsy is unclear. GABA agonists such as muscimol and anticonvulsants such as carbamazepine and phenytoin generally increase the number of spike-wave discharges (SWD). We wanted to verify whether TGB would also facilitate the number of SWD in a genetic rat model for generalized absence epilepsy.

Male WAG/Rij rats with chronically implanted EEG electrodes were given either 0, 1, 3, or 10 mg/kg TGB intraperitoneally. The EEG was recorded for 1 h before and 2 h after drug administration. Behavior was recorded for 30 min postdrug: ambulation, passive behavior, and automatic behavior were scored.